GlobeStar Therapeutics (GlobeStar Therapeutics) Short-Term Debt & Capital Lease Obligation : $0.37 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. GlobeStar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.37 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. GlobeStar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

GlobeStar Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for GlobeStar Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Short-Term Debt & Capital Lease Obligation Chart

GlobeStar Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.11

0.16

0.02

0.36

GlobeStar Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.02	-	0.02	0.36	0.37

GlobeStar Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

GlobeStar Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadewin Avenue, Richland, WA, USA, 99352

Website

https://www.globestarthera.com

GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.

Executives

James C Katzaroff	director, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
William J Farley	director	468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski	officer: CFO	145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship	director, officer: CEO, Pres., Secr., Treas.	14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood	10 percent owner	5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau	director	770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer	director	1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz	director, officer: Interim CEO & Chairman	495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550